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ABSTRACT
Objective To report the incidence of preterm
pre-eclampsia (PE) in women who are screen posi-
tive according to the criteria of the National Institute for
Health and Care Excellence (NICE) and the American
College of Obstetricians and Gynecologists (ACOG),
and compare the incidence with that in those who are
screen positive or screen negative by The Fetal Medicine
Foundation (FMF) algorithm.
Methods This was a secondary analysis of data from the
ASPRE study. The study population consisted of women
with singleton pregnancy who underwent prospective
screening for preterm PE by means of the FMF algorithm,
which combines maternal factors and biomarkers at
11–13 weeks’ gestation. The incidence of preterm PE
in women fulfilling the NICE and ACOG criteria was
estimated; in these patients the incidence of preterm PE
was then calculated in those who were screen negative
relative to those who were screen positive by the FMF
algorithm.
Results A total of 34 573 women with singleton
pregnancy delivering at ≥ 24 weeks’ gestation underwent
prospective screening for preterm PE, of which 239
(0.7%) cases developed preterm PE. At least one of
the ACOG criteria was fulfilled in 22 287 (64.5%)
pregnancies and the incidence of preterm PE was 0.97%
(95% CI, 0.85–1.11%); in the subgroup that was screen
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positive by the FMF algorithm the incidence of preterm
PE was 4.80% (95% CI, 4.14–5.55%), and in those
that were screen negative it was 0.25% (95% CI,
0.18–0.33%), with a relative incidence in FMF screen
negative to FMF screen positive of 0.051 (95% CI,
0.037–0.071). In 1392 (4.0%) pregnancies, at least one
of the NICE high-risk criteria was fulfilled, and in this
group the incidence of preterm PE was 5.17% (95% CI,
4.13–6.46%); in the subgroups of screen positive and
screen negative by the FMF algorithm, the incidence of
preterm PE was 8.71% (95% CI, 6.93–10.89%) and
0.65% (95% CI, 0.25–1.67%), respectively, and the
relative incidence was 0.075 (95% CI, 0.028–0.205).
In 2360 (6.8%) pregnancies fulfilling at least two of the
NICE moderate-risk criteria, the incidence of preterm PE
was 1.74% (95% CI, 1.28–2.35%); in the subgroups of
screen positive and screen negative by the FMF algorithm
the incidence was 4.91% (95% CI, 3.54–6.79%) and
0.42% (95% CI, 0.20–0.86%), respectively, and the
relative incidence was 0.085 (95% CI, 0.038–0.192).
Conclusion In women who are screen positive for
preterm PE by the ACOG or NICE criteria but screen
negative by the FMF algorithm, the risk of preterm PE is
reduced to within or below background levels. The results
provide further evidence to support the personalized
risk-based screening method that combines maternal
factors and biomarkers. Copyright © 2018 ISUOG.
Published by John Wiley & Sons Ltd.
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INTRODUCTION
The current approach to screening for pre-eclampsia (PE)
is to identify risk factors from maternal demographic
characteristics and medical history (maternal factors)1,2.
According to the National Institute for Health and Care
Excellence (NICE), in the UK, women should be con-
sidered to be at high risk of developing PE if they
have any one high-risk factor (hypertensive disease in
previous pregnancy, chronic hypertension, chronic renal
disease, diabetes mellitus or autoimmune disease) or any
two moderate-risk factors (nulliparity, age ≥ 40 years,
body mass index (BMI) ≥ 35 kg/m2, family history of
PE or interpregnancy interval> 10 years)1. In the USA,
according to the American College of Obstetricians and
Gynecologists (ACOG), women are at high-risk of devel-
oping PE if they fulfill any of the following factors:
PE in previous pregnancy, chronic hypertension, chronic
renal disease, diabetes mellitus, systemic lupus erythe-
matosus or thrombophilia, nulliparity, age> 40 years,
BMI ≥ 30 kg/m2, family history of PE or conception by
in-vitro fertilization2. Consequently, the approach recom-
mended by NICE and ACOG essentially treats each risk
factor as a separate screening test with additive detection
rate (DR) and screen-positive rate.
An alternative approach to screening, developed by The
Fetal Medicine Foundation (FMF), allows estimation of
individual patient-specific risks of PE requiring delivery
before a specified gestational age. The approach uses
Bayes’ theorem to combine the a-priori risk from maternal
factors, derived by a multivariable logistic model, with
the results of various combinations of biophysical and
biochemical measurements3,4. In a previous study, we
used data from prospective screening in 35 948 singleton
pregnancies at 11–13 weeks’ gestation to develop an
algorithm for the calculation of patient-specific risk of
PE4. Combined screening by maternal factors, mean
arterial pressure (MAP), uterine artery pulsatility index
(UtA-PI), serum placental growth factor (PlGF) and
serum pregnancy-associated plasma protein-A (PAPP-A)
achieved DR of delivery with PE at < 37 (preterm PE)
and ≥ 37 weeks (term PE) of 75% and 47%, respectively,
at a false-positive rate (FPR) of 10%. This prediction
algorithm was validated prospectively in a multicenter
study of 8775 singleton pregnancies and reported DRs of
75% for preterm PE and 43% for term PE, at 10% FPR5.
In the same cohort, the performance of the FMF algorithm
was compared with those of the screening methods
recommended by NICE and ACOG6. In screening with
use of NICE guidelines, the DR was 39% for preterm PE
and 34% for term PE, at 10.3% FPR, and the respective
DRs with use of ACOG recommendations were 90% and
89%, at 64.3% FPR.
The Combined Multimarker Screening and Random-
ized Patient Treatment with Aspirin for Evidence-Based
Preeclampsia Prevention (ASPRE) trial reported that in
women identified by first-trimester screening as being at
high risk for PE, use of aspirin (150 mg/day from the first
to the third trimester), compared with placebo, reduced
the incidence of preterm PE, which was the primary out-
come, by 62% (95% CI, 26–80%), but had no significant
effect on the rate of term PE7. Since the performance of
screening for preterm PE by the FMF algorithm is superior
to the methods recommended by NICE and ACOG, the
best method of selecting patients that would benefit from
prophylactic use of aspirin is the method recommended
by the FMF. However, obstetricians may be reluctant to
withhold treatment from women who are screen positive
by the NICE or ACOG methods but screen negative by
the FMF method.
The objective of this study was to report the incidence of
preterm PE in women who are screen positive according
to the criteria of NICE and ACOG and compare the
incidence with that in those who are screen positive or
screen negative by the FMF algorithm, in the total screened
population of the ASPRE study.
METHODS
Study design and participants
This was a secondary analysis of a prospective, multicenter
study in singleton pregnancies at 11 + 0 to 13 + 6 weeks’
gestation in women booking for routine pregnancy
care at 13 maternity hospitals in the UK, Spain, Italy,
Belgium, Greece and Israel5,7. Approval for the trial was
obtained from the relevant research ethics committee
and competent authority of each country in which the
trial was conducted. Quality control of screening and
verification of adherence to protocol were performed by
the University College London Comprehensive Clinical
Trials Unit (UCL-CCTU).
The study population consisted of women recruited
during the two phases of the ASPRE study: in the first
phase, participants underwent screening by the FMF
algorithm but no intervention (screening quality study)5,
and in the second phase, women in the high-risk group
were invited to participate in a randomized control trial
(RCT) of use of aspirin vs placebo for prevention of
preterm PE7. Eligibility criteria for the trial were maternal
age ≥ 18 years, no serious mental illness or learning
difficulty and singleton pregnancy with live fetus without
major abnormality demonstrated on the 11–13-week
scan. In this study, we included pregnancies delivered
at ≥ 24 weeks’ gestation. During the screening quality
study, 8775 women were evaluated, and 59 subsequently
developed preterm PE. During the second phase, 25 798
women were screened and 159 developed preterm PE.
FMF test
The FMF test is the previously reported algorithm for
first-trimester assessment of risk for PE by maternal
factors, MAP, UtA-PI, PAPP-A and PlGF4. Maternal
factors were recorded as described previously3 and MAP
was measured using validated automated devices and
standardized protocol8. Left and right UtA-PI were
measured by transabdominal color Doppler ultrasound
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and the average value was recorded9, and serum PAPP-A
and PlGF concentrations were measured by an automated
device (PAPP-A and PlGF 1-2-3™ kits, DELFIA® Xpress
random access platform; PerkinElmer Inc. (Wallac Oy),
Turku, Finland). All operators undertaking the Doppler
studies had received the appropriate Certificate of
Competence from the FMF. Measured values of MAP,
UtA-PI, PAPP-A and PlGF were expressed as multiples
of the median (MoM) adjusting for those characteristics
found to provide a substantive contribution to the log10
transformed value, including maternal factors in the prior
model10–13. Gestational age was determined from the
measurement of fetal crown–rump length14.
Outcome
The outcome measure was preterm PE and the diagnosis
of PE was based on the criteria of the International
Society for the Study of Hypertension in Pregnancy15.
The systolic blood pressure should be ≥ 140 mmHg
and/or the diastolic blood pressure should be ≥ 90 mmHg
on at least two occasions 4 h apart developing after
20 weeks of gestation in previously normotensive women.
Hypertension should be accompanied by proteinuria of
≥ 300 mg in 24 h or two readings of at least ++ on
dipstick analysis of midstream or catheter urine specimens
if no 24-h collection is available. In PE superimposed on
chronic hypertension, significant proteinuria (as defined
above) should develop after 20 weeks of gestation
in women with known chronic hypertension (history
of hypertension before conception or presence of
hypertension at the booking visit before 20 weeks’
gestation in the absence of trophoblastic disease).
Data on pregnancy outcome were collected from
the hospital maternity records of the women. The
obstetric records of all women with pre-existing or
pregnancy-associated hypertension were examined to
determine if the condition was PE.
The incidence of preterm PE in patients fulfilling the
NICE and ACOG criteria was calculated. In the subgroup
of patients participating in the ASPRE trial and allocated
to aspirin, an adjustment was made for the incidence of
preterm PE based on the finding that aspirin was asso-
ciated with a 62% reduction in the incidence of preterm
PE7. In the ACOG and NICE screen-positive patients,
the incidence of preterm PE was estimated separately
for those who were screen positive and those who were
screen negative by the FMF algorithm, using a risk cut-off
of 1 in 100 for preterm PE, and the relative incidence of
preterm PE in the screen-negative to the screen-positive
group was calculated. Medcalc (Medcalc Software,
Mariakerke, Belgium) was used for all data analyses.
RESULTS
The study population consisted of 34 573 pregnancies
that were screened during the first or second phase of the
ASPRE study, of which an estimated 239 (0.7%) cases
developed preterm PE and 630 (1.8%) term PE.
ACOG criteria
In 22 287 (64.5%) of the 34 573 pregnancies, at least
one of the ACOG criteria was fulfilled and this group
included 732 women on aspirin prophylaxis as part of
the ASPRE RCT (Table 1). In this group, the incidence of
preterm PE was 0.97% (95% CI, 0.85–1.11%). Of the
22 287 ACOG screen-positive pregnancies, 3566 (16.0%)
were screen positive by the FMF algorithm and in this
group the incidence of preterm PE was 4.80% (95%
CI, 4.14–5.55%), whereas 18 721 (84.0%) pregnancies
were screen negative by the FMF algorithm and in this
group the incidence of preterm PE was 0.25% (95% CI,
0.18–0.33%). The relative incidence of preterm PE in
FMF negative to FMF positive pregnancies was 0.051
(95% CI, 0.037–0.071). The incidence of preterm PE
for each risk factor in the total group and subgroups of
screen-positive and screen-negative women by the FMF
algorithm is presented in Table 1.
NICE criteria
In 1392 (4.0%) of the 34 573 pregnancies, at least one
of the NICE high-risk criteria was fulfilled and this
group included 142 women on aspirin prophylaxis as
part of the ASPRE RCT. In this group the incidence of
preterm PE was 5.17% (95% CI, 4.13–6.46%). Of the
women who were screen positive by the NICE high-risk
criteria, 781 (56.1%) were screen positive by the FMF
algorithm and in this group the incidence of preterm
PE was 8.71% (95% CI, 6.93–10.89%), whereas in
the 611 (43.9%) pregnancies that were screen negative
by the FMF algorithm the incidence was 0.65% (95%
CI, 0.25–1.67%) (Table 1). The relative incidence of
preterm PE in FMF screen-negative to FMF screen-positive
pregnancies was 0.075 (95% CI, 0.028–0.205).
In 2360 (6.8%) pregnancies, at least two of the
NICE moderate-risk criteria were fulfilled and in this
group the incidence of preterm PE was 1.74% (95%
CI, 1.28–2.35%). Of these, 692 (29.3%) pregnancies
were screen positive by the FMF algorithm and in this
group the incidence of preterm PE was 4.91% (95% CI,
3.54–6.79%), whereas in the 1668 (70.7%) pregnancies
that were screen negative by the FMF algorithm the
incidence was 0.42% (95% CI, 0.20–0.86%). The relative
incidence of preterm PE in FMF screen-negative to




This study demonstrates that, in the screened population
of the ASPRE trial, the incidence of preterm PE was
0.7% and this was increased in subgroups of women with
risk factors described by ACOG and NICE. The highest
risk factors were chronic hypertension, history of PE in
a previous pregnancy and diabetes mellitus, which were
associated with a 15-fold, 7-fold and 7-fold, respectively,
Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2018.
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Table 1 Incidence of preterm (<37 weeks) pre-eclampsia (PE) by risk factors of the American College of Obstetricians and Gynecologists
(ACOG)2 criteria and high- and moderate-risk factors of the National Institute of Health and Care Excellence (NICE)1 criteria, in the total
group (n = 34 573) of women screened during the ASPRE study and subgroups of screen positive and screen negative women by the FMF
algorithm4
ACOG/NICE screen positive*
Screening criteria Total FMF screen positive FMF screen negative Relative incidence
ACOG risk factors
Any one risk factor 217/22287 (0.97, 0.85–1.11) 171/3566 (4.80, 4.14–5.55) 46/18721 (0.25, 0.18–0.33) 0.051 (0.037–0.071)
Previous PE 35/708 (4.94, 3.58–6.80) 33/410 (8.05, 5.79–11.09) 2/298 (0.67, 0.18–2.41) 0.083 (0.020–0.345)
Chronic hypertension 44/419 (10.50, 7.92–13.80) 43/321 (13.40, 10.10–17.56) 1/98 (1.02, 0.18–5.56) 0.076 (0.011–0.546)
Diabetes mellitus 14/275 (5.09, 3.06–8.36) 12/124 (9.68, 5.62–16.16) 2/151 (1.32, 0.36–4.70) 0.137 (0.031–0.600)
APS/SLE 3/107 (2.80, 0.96–7.92) 3/29 (10.34, 3.58–26.39) 0/78 (0.00, 0.00–4.69) 0.000 (0.000–0.470)
Nulliparity 151/17161 (0.88, 0.75–1.03) 115/2686 (4.28, 3.58–5.11) 36/14475 (0.25, 0.18–0.34) 0.058 (0.040–0.084)
Age>40 years 13/1486 (0.87, 0.51–1.49) 11/303 (3.63, 2.04–6.38) 2/1183 (0.17, 0.05–0.61) 0.047 (0.010–0.209)
BMI ≥ 30 kg/m2 81/6225 (1.30, 1.05–1.61) 66/1241 (5.32, 4.20–6.71) 15/4984 (0.30, 0.18–0.50) 0.057 (0.032–0.099)
Family history of PE 23/1613 (1.43, 0.95–2.13) 19/368 (5.16, 3.33–7.92) 4/1245 (0.32, 0.13–0.82) 0.062 (0.021–0.182)
In-vitro fertilization 12/991 (1.21, 0.69–2.10) 8/195 (4.10, 2.09–7.89) 4/796 (0.50, 0.20–1.28) 0.123 (0.037–0.403)
NICE high-risk factors†
Any one factor 72/1392 (5.17, 4.13–6.46) 68/781 (8.71, 6.93–10.89) 4/611 (0.65, 0.25–1.67) 0.075 (0.028–0.205)
NICE moderate-risk
factors‡
Any two or more factors 41/2360 (1.74, 1.28–2.35) 34/692 (4.91, 3.54–6.79) 7/1668 (0.42, 0.20–0.86) 0.085 (0.038–0.192)
Any two or more factors
including:
Nulliparity 34/1888 (1.80, 1.29–2.51) 28/548 (5.11, 3.56–7.29) 6/1340 (0.45, 0.21–0.97) 0.088 (0.037–0.211)
Age ≥ 40 years 10/768 (1.30, 0.71–2.38) 8/212 (3.77, 1.92–7.27) 2/556 (0.36, 0.10–1.30) 0.095 (0.020–0.445)
BMI ≥ 35 kg/m2 21/976 (2.15, 1.41–3.27) 17/339 (5.01, 3.15–7.88) 3/637 (0.47, 0.16–1.38) 0.094 (0.028–0.318)
Family history of PE 18/928 (1.94, 1.23–3.05) 15/263 (5.70, 3.49–9.20) 3/665 (0.45, 0.15–1.32) 0.079 (0.023–0.271)
Interpregnancy
interval>10 years
2/276 (0.72, 0.20–2.60) 2/75 (2.67, 0.73–9.21) 0/201 (0.00, 0.00–1.88) 0.075 (0.004–1.550)
Data are given as n/N (%, 95% CI) or % (95% CI). *Incidence of preterm PE estimated after adjustment for effect of aspirin in those
receiving this treatment. †NICE high-risk factors: hypertensive disease in previous pregnancy, chronic hypertension, chronic renal disease,
diabetes mellitus, autoimmune disease. ‡NICE moderate-risk factors: nulliparity, age ≥ 40 years, BMI ≥ 35 kg/m2, family history of PE,
interpregnancy interval> 10 years. APS, antiphospholipid syndrome; BMI, body mass index; SLE, systemic lupus erythematosus.
increase in incidence of preterm PE, compared with the
background levels. There was also a 2-fold increase in
incidence of preterm PE associated with obesity, family
history of PE and conception by in-vitro fertilization. In
the case of nulliparity and increased maternal age, the
incidence of preterm PE was not significantly higher than
the background.
The study also demonstrates that, in women who
were screen positive by the ACOG or NICE criteria, the
incidence of preterm PE increased substantially in those
who were also screen positive by the FMF algorithm,
whereas in the FMF screen-negative group the incidence
was reduced to within or below background levels.
In the group fulfilling any one of the ACOG criteria,
the incidence of preterm PE in the subgroup of FMF
screen-negative pregnancies was 95% lower than in the
screen-positive group. Similarly, in women fulfilling any
one of the NICE high-risk criteria, the incidence of preterm
PE in the subgroup of FMF screen-negative pregnancies
was 92% lower than in the screen-positive group, and
for those with any two or more moderate-risk factors the
reduction was 91%.
Strengths and limitations
This was a large study of prospectively collected data on
maternal characteristics, medical history and biomarkers
in women attending for routine care in a gestational age
range that is widely used for diagnosis of major fetal
defects and screening for fetal trisomies. Measurement of
all biomarkers was recorded in all cases and consistency
in data collection was maintained throughout the study
period by ensuring adequate training of all investigators
based on standardized protocols, and regular UCL-CCTU
monitoring.
The main limitation of the study relates to the low
number of cases of women with certain risk factors,
such as antiphospholipid syndrome or systemic lupus
erythematosus, and the small number of cases of preterm
PE leading to the inevitable wide CIs obtained for
relative risks. Nevertheless, there was a major reduction
in incidence of preterm PE in the FMF screen-negative
group relative to that in the screen-positive group.
Implications for practice
Traditionally, screening for PE was based on a series of
maternal factors and women in the high-risk group were
offered aspirin (75–80 mg/day) with the aim of reducing
the risk of PE by about 10%1,2,16. Recent evidence
suggests that the target for first-trimester screening should
be severe PE leading to preterm birth, rather than all
types of PE. Aspirin is considerably more effective than
previously thought in reducing the risk of preterm PE;
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a recent meta-analysis reported that aspirin reduces the
risk of preterm PE by 67%, provided the daily dose of
the drug is ≥ 100 mg and the gestational age at onset of
therapy is ≤ 16 weeks, whereas aspirin had no effect on
the incidence of term PE17. The performance of screening
for preterm PE, and therefore appropriate selection of
the patients that would benefit from prophylactic use of
aspirin, is by far superior if the FMF algorithm is used
than the method advocated by ACOG and NICE1–6.
The study confirmed that with most risk factors
described by ACOG and NICE, the incidence of preterm
PE is increased. However, the main issue is whether
women that fulfill the ACOG or NICE screening criteria
but are screen negative by the FMF method should in
any case receive aspirin. We have shown that in such
women the incidence of preterm PE is reduced to within
or below background levels. Consequently, in screening
for preterm PE, known risk factors should be combined
with various biophysical and biochemical markers to
determine if the patient-specific risk is high or low before
deciding whether or not they should be advised to take
aspirin.
Lessons can be learned from the implementation of
screening for fetal trisomies. In the 1970s, the method
of screening was solely dependent on maternal age, but
in the subsequent decades a series of biophysical and
biochemical markers were described18. It is now accepted
that the best approach of selecting the high-risk group in
need of further investigations is the use of Bayes’ theorem
to combine maternal age with a series of biomarkers
to determine the patient-specific risk, rather than use of
arbitrary cut-offs in maternal age or biomarker levels.
ACOG and NICE guidelines should be updated
to reflect recent scientific evidence that the screening
target should be preterm PE, the best way to identify
the high-risk group is by a combination of maternal
factors and biomarkers, aspirin should be started before
16 weeks’ gestation and the daily dose should be higher
than 100 mg.
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